Topic: Addyi

The FDA approved Addyi, a drug marketed as "female Viagra" to treat hypoactive sexual desire disorder (HSDD). The hosts criticize the approval, characterizing it as the result of a sophisticated public relations campaign called "Even the Score" rather than sound science. They highlight significant side effects including nausea, sleepiness, and fainting when combined with alcohol.

The approval of Addyi, the "little pink pill" for female sexual dysfunction, is linked to the widespread use of SSRI antidepressants. A producer's personal story illustrates how antidepressants can eliminate sexual desire, creating a secondary market for drugs intended to restore libido.